Four years ago, Dendreon (DNDN) was the darling of the biotech sector with a promising cancer vaccine awaiting FDA approval and a stock price sitting above $50 a share. Today, Dendreon sits just above $2 and CEO John Johnson is out the door after resigning for what the company calls “personal reasons.” Cantor Fitzgerald analyst [...]